4-(3-nitrophenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester | 138647-55-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(3-nitrophenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl 4-(3-nitrophenyl)-5,6-dihydropyridine-1(2H)-carboxylate；tert-butyl 1,2,3,6-tetrahydro-4-(3-nitrophenyl)pyridine-1-carboxylate；Tert-butyl 4-(3-nitrophenyl)-3,6-dihydro-1(2H)-pyridinecarboxylate；tert-butyl 4-(3-nitrophenyl)-3,6-dihydro-2H-pyridine-1-carboxylate
• CAS: 138647-55-9
• 化学式: C₁₆H₂₀N₂O₄
• 分子量: 304.346
• InChiKey: ILZZTMHEDJZXJK-UHFFFAOYSA-N

物化性质

• 沸点：
  425.0±45.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  75.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(3-nitrophenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 为溶剂， 20.0 ℃ 、275.8 kPa 条件下， 反应 16.0h， 以88.1%的产率得到4-(3-氨基苯基)-哌啶-1-羧酸叔丁酯
  参考文献：
  名称：

  [EN] BRAF DEGRADERS
  [FR] AGENTS DE DÉGRADATION DE BRAF

  摘要：

  本发明提供了能够特异性降解BRAF的化合物。这些化合物可用于治疗各种癌症。

  公开号：

  WO2021255212A1
• 作为产物：
  描述：

  N-叔丁氧羰基-4-哌啶酮 在 四(三苯基膦)钯 sodium carbonate 、 lithium chloride 、 lithium diisopropyl amide 作用下， 以 乙二醇二甲醚 为溶剂， 反应 6.33h， 生成 4-(3-nitrophenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Coupling of Arylboronic Acids with a Partially Reduced Pyridine Derivative

  摘要：

  制备了叔丁基碳酰基1,2,3,6-四氢-4-[(三氟甲基)磺酰氧基]吡啶-1-羧酸酯(2)，并将其在钯催化下与多种取代的芳基硼酸3进行偶联反应，生成了一系列叔丁基-4-芳基-1,2,3,6-四氢吡啶-1-羧酸酯4。

  DOI：

  10.1055/s-1991-26626

文献信息

• Substituted anilinic piperidines as MCH selective antagonists
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US06727264B1

  公开（公告）日：2004-04-27

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therepeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

  这项发明涉及对黑素集中激素-1（MCH1）受体具有选择性的拮抗剂化合物。发明提供了一种药物组合物，包括治疗有效量的本发明化合物和药用可接受载体。本发明还提供了一种通过结合本发明的治疗有效量的化合物和药用可接受载体来制造的药物组合物。本发明进一步提供了一种制造药物组合物的方法，包括结合治疗有效量的本发明化合物和药用可接受载体。
• 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE
  申请人：Player R. Mark

  公开号：US20080114007A1

  公开（公告）日：2008-05-15

  The invention addresses the current need for selective and potent protein tyrosine kinase inhibitors by providing potent inhibitors of c-fms kinase. The invention is directed to the novel compounds of Formula I: or a salt, stereoisomer, tautomer, crystalline, polymorph, amorphous, solvate, hydrate, ester, prodrug or metabolite form thereof, wherein A, Y, Z, R 101 and R 200 are described in the specification.

  本发明针对当前对选择性和强效蛋白酪氨酸激酶抑制剂的需求，提供对c-fms激酶的强效抑制剂。本发明涉及以下式I的新化合物： 或其盐、对映体、互变异构体、结晶、多晶型、无定形、溶剂化物、水合物、酯、前药或代谢物形式，其中A、Y、Z、R 101 和R 200 在说明书中有描述。
• [EN] VEGFR3 INHIBITORS<br/>[FR] INHIBITEURS DE VEGFR3
  申请人：CANCER THERAPEUTICS CRC PTY LTD

  公开号：WO2014026243A1

  公开（公告）日：2014-02-20

  This invention relates to a compound of the formula (I): The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer, as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphangiogenesis.

  这项发明涉及一种化合物，其化学式为(I)。该发明还涉及制备化合物(I)的方法，含有该化合物的药物剂或组合物，或者使用该化合物治疗增殖性疾病（如癌症）以及通过控制和/或抑制淋巴管生成改善疾病的方法。
• [EN] TARGETED PROTEIN DEGRADATION<br/>[FR] DÉGRADATION CIBLÉE DE PROTÉINES
  申请人：C4 THERAPEUTICS INC

  公开号：WO2020132561A1

  公开（公告）日：2020-06-25

  This invention provides pharmaceutical protein degraders and E3 ubiquitin ligase binders for therapeutic applications as described further herein.

  这项发明提供了用于治疗应用的药用蛋白质降解剂和E3泛素连接酶结合物。
• DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
  申请人：——

  公开号：US20030082623A1

  公开（公告）日：2003-05-01

  This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors. This invention provides a method of modifying the feeding behavior of a subject which comprises administering to the subject an amount of an MCH1 antagonist effective to decrease the body mass of the subject and/or decrease the consumption of food by the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of an MCH1 antagonist effective to treat the subject's depression and/or anxiety.

  这项发明提供了编码人类MCH1受体的孤立核酸，纯化的人类MCH1受体，包括编码人类MCH1受体的孤立核酸的载体，包含这种载体的细胞，针对人类MCH1受体的抗体，用于检测编码人类MCH1受体的核酸探针，互补于编码人类MCH1受体独特序列的反义寡核苷酸，表达编码正常或突变人类MCH1受体的转基因非人类动物，孤立人类MCH1受体的分离方法，治疗与人类MCH1受体活性相关的异常的方法，以及确定化合物与哺乳动物MCH1受体结合的方法。这项发明提供了一种修改受试者摄食行为的方法，包括向受试者投与足以减少受试者体重和/或减少受试者食物摄入量的MCH1拮抗剂的量。这项发明还提供了一种治疗患有抑郁和/或焦虑的受试者的方法，包括向受试者投与足以治疗受试者抑郁和/或焦虑的MCH1拮抗剂的量。